It was announced on Friday that the European Medicines Agency (EMA) has said that it has recommended revoking the marketing authorisation for a drug manufactured by Swiss-American pharmaceutical firm Novartis, Economic Times has reported.
The drug, Adakveo, had been developed against sickle cell disease.
A review by EMA's human medicines committee (CHMP) said that the drug could come with significant health risks.
The review concluded that the drug could cause severe and serious treatment-related side effects.
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Evommune signs strategic collaboration with Maruho Co
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Sanofi granted Priority Review for EoE treatment in young children
Valneva secures USD32m IXIARO vaccine contract with US DoD
Sanofi's ALTUVIIIO gains Japanese approval as haemophilia A factor VIII therapy
Seagen and Astellas Pharma report positive outcomes in advanced bladder cancer trial
Mabwell's 9MW3011 receives US FDA Fast Track Designation
89bio receives FDA Breakthrough Therapy Designation for pegozafermin in NASH treatment
Hepagene Therapeutics' HPG7233 IND application receives US FDA approval
Pulmatrix PUR3100 investigational new drug application receives US FDA acceptance
BeiGene regains full rights to anti-PD-1 antibody TEVIMBRA (tislelizumab) from Novartis